MRMD (MariMed) EPS without NRI: $-0.03 (TTM As of Mar. 2026)


What is MariMed EPS without NRI?

MariMed MRMD EPS without NRI is $-0.03 as of Mar. 2026. The stock has 5 warning signs investors should review. Among 786 Drug Manufacturers companies, MariMed ranks worse than 127226.34% on this metric.

MariMed's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $-0.01. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.03.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for MariMed's EPS without NRI or its related term are showing as below:

During the past 13 years, MariMed's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 71.10% per year. The lowest was -242.70% per year. And the median was 20.85% per year.

MRMD's 3-Year EPS without NRI Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 9.65
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

MariMed's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.03.

MariMed's EPS (Basic) for the three months ended in Mar. 2026 was $-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.03.


MariMed  (OTCPK:MRMD) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


MariMed EPS without NRI Related Terms


MariMed EPS without NRI Historical Data

* Premium members only.

The historical data trend for MariMed's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MariMed EPS without NRI Chart

MariMed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.05 -0.02 -0.03 -0.04

MariMed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 0.00 -0.01 -0.01 -0.01

MRMD vs RMTI, CPHI, TXMD: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MariMed PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MariMed's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where MariMed's PE Ratio without NRI falls into.



MariMed EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-0.03 mean?
MariMed (MRMD) has a EPS without NRI of $-0.03 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on MariMed and its competitors. According to the industry distribution chart, MariMed ranks #999999 out of 786 companies in the Drug Manufacturers industry.
Is MariMed's EPS without NRI too high?
MariMed's current EPS without NRI is $-0.03. Based on the distribution chart, MariMed ranks #999999 out of 786 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does MariMed's EPS without NRI compare to RMTI and CPHI?
According to the Drug Manufacturers industry distribution chart, MariMed ranks #999999 out of 786 companies for EPS without NRI. This places MariMed in the lower half of its industry. The industry median EPS without NRI is 9.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.65, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on MariMed and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MariMed's current EPS without NRI is $-0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MariMed stock overvalued right now?
Based on GuruFocus' analysis, MariMed (MRMD) is currently considered Possible Value Trap. The stock's GF Value™ is $0.16, compared to a current price of $0.07 — trading 57.7% below its estimated fair value. The current EPS without NRI is $-0.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For MariMed (MRMD), the current EPS without NRI is $-0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MariMed Business Description

Other Exchanges MRMD:Canada
Address 10 Oceana Way, Floor 2, Norwood, MA, USA, 02062
MariMed Inc is a multi-state cannabis operator in the United States dedicated to improving lives every day through its high-quality products. The company develops, owns, and manages seed to sale state-licensed, regulatory-compliant facilities for the cultivation, production, and dispensing of medicinal and adult-use cannabis. It has created and continues to develop its own brands of cannabis flower, concentrates, edibles, and other precision-dosed products utilizing its proprietary strains and formulations. The company also licenses its proprietary brands, along with other top cannabis products, in select domestic markets. Its operations are conducted in compliance with applicable state and local laws and regulations in the jurisdictions in which it operates.